Beyond oncology, a VHL-recruiting PROTAC was designed to degrade SMAD family member 3 (Smad3), a key mediator of fibrosis, while stabilizing hypoxia-inducible factor 2 alpha (HIF-2α), a protective factor in kidney disease. This evidence concerns the gene SMAD3 and kidney disorder.